- Wondering whether Encompass Health at around US$97.52 is offering value or asking you to overpay? This piece breaks down what the current price might be telling you.
- The stock has pulled back recently, with a 3.9% decline over 7 days, an 8.5% decline over 30 days and an 8.3% decline year to date, while the 1 year return sits at a 1.8% decline and the 3 year and 5 year returns are 89.0% and 57.8% respectively.
- These moves are playing out against a backdrop of ongoing attention on US healthcare services and rehabilitation providers, where investor focus often shifts between growth potential and defensiveness. For Encompass Health, that context matters because it shapes how much of the current share price may be driven by sentiment rather than underlying value.
- On Simply Wall St's 6 point valuation framework, Encompass Health scores a perfect 6 out of 6. The rest of this article will break down what different valuation approaches suggest about the stock, before finishing with a way to think about valuation that helps tie those methods together.
Approach 1: Encompass Health Discounted Cash Flow (DCF) Analysis
A Discounted Cash Flow, or DCF, model projects a company’s future cash flows and then discounts them back to today’s value to estimate what the business might be worth per share.
For Encompass Health, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow stands at about $452.7 million. Analyst inputs and extrapolations from Simply Wall St project free cash flow of $484.5 million in 2026 and $550.0 million by 2028, with further estimates extending out to 2035.
Bringing all of those projected cash flows back to today using a discount rate gives an estimated intrinsic value of $144.60 per share under this DCF. Versus the recent share price of about $97.52, this suggests an intrinsic discount of roughly 32.6%, indicating that the shares are trading below the DCF estimate of value.
Result: UNDERVALUED
Our Discounted Cash Flow (DCF) analysis suggests Encompass Health is undervalued by 32.6%. Track this in your watchlist or portfolio, or discover 55 more high quality undervalued stocks.
Approach 2: Encompass Health Price vs Earnings
For profitable companies, the P/E ratio is a useful shorthand because it links what you pay per share to the earnings that each share generates. It helps you see how much the market is willing to pay for a dollar of earnings.
What counts as a “normal” or “fair” P/E depends on expectations for future growth and the risk investors see in those earnings. Higher expected growth or lower perceived risk can justify a higher P/E, while slower growth or higher risk usually points to a lower multiple.
Encompass Health currently trades on a P/E of about 17.1x. That sits below the Healthcare industry average of around 21.2x and also below the peer group average of about 20.6x. Simply Wall St’s Fair Ratio for Encompass Health is higher, at roughly 27.0x. The Fair Ratio is a proprietary estimate of what the P/E could be given factors such as earnings growth, industry, profit margins, market cap and specific risks.
Compared with simple peer or industry averages, the Fair Ratio is designed to be more tailored because it adjusts for those company specific drivers rather than assuming one size fits all.
With a Fair Ratio of about 27.0x versus the current 17.1x, Encompass Health screens as trading below this tailored P/E estimate.
Result: UNDERVALUED
P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.
Upgrade Your Decision Making: Choose your Encompass Health Narrative
Earlier it was mentioned that there is an even better way to understand valuation. Meet Narratives, a simple tool on Simply Wall St's Community page that lets you put a clear story around your numbers by linking your view of Encompass Health's future revenue, earnings and margins to a forecast, a Fair Value and then a comparison with the current price. All of this automatically updates as new news or earnings arrive. For example, one investor might build a Narrative that leans on the US$99.17 fair value and more moderate assumptions around rehabilitation demand, while another leans on the US$142.73 fair value with stronger assumptions about hospital expansion and profitability. The platform lets you see those different stories side by side to help decide how the current share price lines up with the view you find most reasonable.
Do you think there's more to the story for Encompass Health? Head over to our Community to see what others are saying!
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com